anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Currently available electrophysiological approaches are limited in their ability to identify the majority of patients with CAD and LV dysfunction that succumb to sudden cardiac death (SCD). Half of the patients developing SCD are not inducible at electrophysiological testing underscoring the need for new ways to identify substrates leading to arrhythmic death. Viable chronically dysfunctional with reduced resting flow, or hibernating myocardium, not amenable to revascularization appears to be a major risk factor for subsequent cardiac death and is present in up to 60% of patients with ischemic cardiomyopathy. Cause specific mortality data is limited but appears to be arrhythmic rather than from fatal myocardial infarction or progressive heart failure. Revascularization improves survival but most patients with hibernating myocardium are managed medically due to prohibitive procedural risks or technical limitations. Basic studies in swine with hibernating myocardium demonstrate SCD arising from VT/VF in the absence of myocardial scar or heart failure. The central hypothesis of this proposal is that the presence of hibernating myocardium as opposed to scar identifies a large subset of patients with ischemic cardiomyopathy that are at high risk for SCD. We further hypothesize that this risk is related to inhomogeneity in sympathetic innervation arising from chronic repetitive ischemia. PAREPET is a prospective observational study that will enroll patients with coronary disease, Class I-III heart failure and an ejection fraction ≤35%. Using positron emission tomography (PET), the frequency and amount of hibernating myocardium will be quantified in patients that are not candidates for coronary revascularization. Three Specific Aims are proposed. Aim 1 will determine whether imaging the mismatch between viability (preserved 18F-2-deoxyglucose) and reduced resting flow (13NH3) can predict an increased risk of SCD (or ICD discharge for VT/VF as a surrogate end-point) in hibernating myocardium. Aim 2 will image norepinephrine uptake using 11C-hydroxyephedrine to determine whether inhomogeneity in myocardial sympathetic innervation predicts SCD risk better than viability testing. Aim 3 will identify whether the substrate identified by PET is stable after an aborted SCD event by evaluating temporal changes in function, viability and sympathetic innervation in patients with an ICD. Our long-term objective is to develop better approaches to identify patients with CAD who are most likely to benefit from primary prevention of SCD with placement an ICD.
OBJECTIVE: Digoxin is a cardiac glycoside for treating heart failure and atrial fibrillation. Despite its limited therapeutic range and complex pharmacokinetic properties, this medication continues to be frequently prescribed. This study aimed to evaluate the serum digoxin concentration (SDC) at therapeutic, subtherapeutic, and toxic levels and explore the factors affecting these levels in patients receiving digoxin therapy for heart failure.
PATIENTS AND METHODS: In this descriptive and cross-sectional study, the data were obtained from the electronic system of patients who presented to Afyonkarahisar Health Sciences University. For the SDC, the reference range was accepted as 0.5-0.9 ng/mL, and the upper limit was 2.0 ng/mL. The patient's demographic characteristics, comorbidities, and laboratory findings were evaluated. The Mann-Whitney U test, Chi-square test, and logistic regression analysis were used. p<0.05 was considered statistically significant.
RESULTS: The data of 419 patients (mean age: 65.9±16.1 years, 68.5% women) were evaluated. The mean SDC was 1.11±1.01 ng/mL, and it was below 0.5 ng/mL in 24.3% of the patients, 0.5-0.9 ng/mL in 23.4%, 0.9-2 ng/mL in 41.3%, and over 2 ng/mL in 11.1%. Age, male gender, the presence of diabetes mellitus, and high HbA1c values were found to be associated with greater SDC levels, but this was not statistically significant. The presence of renal failure, elevated creatinine and magnesium levels, and potassium, sodium, and calcium levels outside the normal limits significantly increased the SDC. High creatinine and low/high potassium values significantly affected the detection of SDC at the toxic level.
CONCLUSIONS: The measurement of SDC levels holds significance not only in the monitoring of toxicity but also in ensuring adherence to the recommended therapeutic range during therapy. It is recommended to exercise caution in terms of risk factors such as age, kidney function test results, and blood electrolyte levels.
There is only one arm in this study. A range of variables will first be measured (daily and weekly) over a baseline period in a group of participants. Following this baseline period, participants will be take part in an MBCT intervention whilst the same variables are measured. Following the intervention,there will be a 4-week follow-up period, and MBCT groups will not run during this time.
JNJ-70033093 is an oral anticoagulant for prevention and treatment of thromboembolic events (for example, VTE) that binds and inhibits activated form of human coagulation Factor XI (FXIa) with high affinity and selectivity. The study will consist of 3 phases: up to 30-day screening phase before total knee replacement (TKR) surgery, 10 to14 day postoperative dosing phase, and 4-week follow-up phase. The hypothesis of this study is JNJ-70033093 reduces risk of total VTE during treatment period. The total duration of participation following randomization will be approximately 6 weeks. Efficacy evaluations include unilateral venography assessment of operated leg and assessments of symptomatic DVT, PE, or death. Safety evaluation includes adverse events, clinical laboratory tests, and physical examinations. The safety and efficacy will be monitored throughout the study.
A Policy Enforcement Point (PEP) enforcement module ( 100 ) comprises: a monitor ( 110 ), ( 120, 130, 140 ) for monitoring the output of a policy controlled module or PEP ( 200 ) operating within a distributed computer system and a correction performer module ( 150 ). The PEP ( 200 ) is associated with one or more policies ( 400 ) which are applied to the PEP. Each policy specifies a trigger event or events and an action or actions to be performed as a result of the trigger event occurring as well as expected output from the PEP ( 200 ) when it performs a specified action or actions. The monitor monitors output produced by the PEP ( 200 ) as a result of operating in compliance with a policy, and it compares the monitored output with one or more specified expected outputs specified in the policy. In the event that the comparison indicates a divergence between the expected and observed outputs a correction evaluator ( 140 ) evaluates an appropriate corrective action to take and issues a request to the correction performer module to perform such corrective action. The correction performer module ( 150 ) then performs the corrective actions as specified by the correction evaluator ( 140 ).
Recent evidence from both observational and experimental studies indicates that disobeying our normal day-night rhythm negatively influences our metabolic and cardiovascular health, possibly leading to obesity and type 2 diabetes mellitus (T2DM). An important hallmark of obesity and T2DM is a decreased skeletal muscle mitochondrial function. Interestingly, recent research indicates that also skeletal muscle mitochondrial function under the influence of a day-night rhythm. The main objective of this study is to investigate the presence of a day-night rhythm in skeletal muscle energy metabolism (in particular mitochondrial function) of healthy young participants. Therefore, subjects will stay at the research unit for 44 hours, with standardized meals and sleeping time. During this period we will take five muscle biopsies, perform indirect calorimetry measurements and blood draws.
Side effects of Orphenadrine Citrate, Aspirin and Caffeine Tablets are those seen with aspirin and caffeine or those usually associated with mild anti-cholinergic agents. These may include tachycardia, palpitation, urinary hesitancy or retention, dry mouth, blurred vision, dilation of the pupil, increased intraocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, and rarely, urticaria and other dermatosis. Infrequently, an elderly patient may experience some degree of confusion. Mild central excitation and occasional hallucinations may be observed. These mild side effects can usually be eliminated by reduction in dosage. One case of aplastic anemia associated with the use of orphenadrine citrate, aspirin and caffeine has been reported. No causal relationship has been established. Rare G.I. hemorrhage due to aspirin content may be associated with the administration of Orphenadrine Citrate, Aspirin and Caffeine Tablets. Some patients may experience transient episodes of light-headedness, dizziness or syncope.
Participants will receive placemats promoting healthier featured kids' meals and the opportunity to redeem their kids' meal token for a toy instead of dessert. Families will also receive a frequent diner card, which after purchasing one of the featured healthier kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period. Corresponding signage will be displayed in the restaurant.
In the last decade, there has been an increased interest in exploring the impact of the birth environment on midwifery practice and the women's birth experiences. Results from these studies show that a home-like birth environment has positive effects on both midwifery practice and the birth experience. The hormone oxytocin that causes contractions during labour may play an important role in this context. The hormone is released when being in a safe, secure and confident environment. Therefore, it is a reasonable assumption that the birth environment also has an impact on birth outcomes.

To investigate this assumption one traditional labour room was transformed to an experimental labour room. The design of the room is inspired by knowledge from evidence-based healthcare design, which describes bringing nature into the room. Furthermore, it is possible for the parents to design their own birth setting by choosing atmosphere through sound, light and nature scenes.
The present invention relates to a method for extracting and separating effective parts from dogbane, which comprises the following steps of a preparation step in which dogbane liquid is applied to columns, a step in which separation is carried out by the separation columns, a step in which the separation columns are eluted by eluting agents and a step in which eluent is condensed. The separation columns are macroporous adsorption resin columns. The separation columns are firstly eluted by 20 to 39% of ethanol water solution, and subsequently eluted by 40 to 70% of ethanol water solution in the elution step. Otherwise, the macroporous adsorption resin columns can be firstly eluted by water until the eluent becomes colorless in the elution step. In the separating method, the content of effective parts in extract formed after 40 to 70% of eluent is condensed is high, and the total content of flavone is higher than 50%. The extract meets the standard of the raw material medicine of traditional Chinese medicine, class II. In addition, the eluting agents used by the method do not have toxicity, and are suitable for industrial production. Therefore, the method provides an efficient and feasible method for purifying and producing a raw material medicine, class II, specifically the dogbane. The method is suitable for industrial application, and lays foundation for the further research of dogbane preparations.
No rehabilitative interventions except sphincter and speech rehabilitation and psychological support, are admitted for the 12 weeks of participation to the project and the following 6 weeks before Follow-up evaluations (a total of 18 weeks). The execution of unspecific physical activities, if not already practiced, will be suggested to the participants.
This group will receive the capsaicin. The Study Drug ICX72 or sinus buster which is a homeopathic blend of capsicum annum and eucalyptol, that is readily available over the counter.
Neuroinflammation plays important roles in retinal ganglion cell (RGC) degeneration in glaucoma. MicroRNA-146 (miR-146) has been shown to regulate inflammatory response in neurodegenerative diseases. In this study, whether and how miR-146 could affect RGC injury in chronic ocular hypertension (COH) experimental glaucoma were investigated. We showed that in the members of miR-146 family only miR-146a-5p expression was upregulated in COH retinas. The upregulation of miR-146a-5p was observed in the activated microglia and Müller cells both in primary cultured conditions and in COH retinas, but mainly occurred in microglia. Overexpression of miR-146a-5p in COH retinas reduced the levels pro-inflammatory cytokines and upregulated the levels of anti-inflammatory cytokines, which were further confirmed in the activated primary cultured microglia. Transfection of miR-146a-5p mimic increased the percentage of anti-inflammatory phenotype in the activated BV2 microglia, while transfection of miR-146a-5p inhibitor resulted in the opposite effects. Transfection of miR-146a-5p mimic/agomir inhibited the levels of interleukin-1 receptor associated kinase (IRAK1) and TNF receptor associated factor 6 (TRAF6) and phosphorylated NF-κB subunit p65. Dual luciferase reporter gene assay confirmed that miR-146a-5p could directly target IRAK1 and TRAF6. Moreover, downregulation of IRAK1 and TRAF6 by siRNA techniques or blocking NF-κB by SN50 in cultured microglia reversed the miR-146a-5p inhibitor-induced changes of inflammatory cytokines. In COH retinas, overexpression of miR-146a-5p reduced RGC apoptosis, increased RGC survival, and partially rescued the amplitudes of photopic negative response. Our results demonstrate that overexpression of miR-146a-5p attenuates RGC injury in glaucoma by reducing neuroinflammation through downregulating IRAK1/TRAF6/NF-κB signaling pathway in microglia.
Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study.
EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks. Recombinant human erythropoietin was configured by the hospital pharmacy intravenous Centre Configuration, melted configured with saline to 1ml/kg solution.
Myocardial ischemia-reperfusion injury (IRI) after myocardial ischemia, cardiac surgery, or circulatory arrest leads to adverse cardiovascular outcomes. Primarily, no blood flow to the heart causes an imbalance between oxygen demand and supply, namely, ischemia, resulting in damage or dysfunction of the cardiac tissue. Early restoration of blood flow has been established to be the treatment of choice to prevent further tissue injury. Indeed, the use of thrombolytic therapy or primary percutaneous coronary intervention is the most effective strategy for reducing the size of a myocardial infarct and improving the clinical outcome. Unfortunately, restoring blood flow to the ischemic myocardium, named reperfusion, can also contribute to injury. This phenomenon was therefore termed myocardial IRI. Subsequent studies in animal models of acute myocardial infarction suggest that myocardial IRI accounts for up to 50% of the final size of a myocardial infarct. Consequently, many researchers aim to understand the underlying molecular mechanism of myocardial IRI to find therapeutic strategies that ultimately reduce the final infarct size. Despite numerous therapeutic strategies identified in laboratories, no clinical medicine specifically targeting IRI has yet been approved. Therefore, more relevant research is needed to develop promising therapeutic agents. In this respect, we will introduce a solid and reproducible experimental protocol to induce myocardial IRI in mice and test potent drug transfer during this surgical procedure.
Participants receive standard chemotherapy educational materials. Participants also complete surveys over approximately 22 minutes at the time of first chemotherapy infusion, and approximately 8 weeks after first chemotherapy infusion.
PURPOSE: To obtain a nonaerosol type foamy composition for the oral cavity, filled in a nongas atmospheric-pressure container, foamable in use, applicable to brushing, excellent in dispersibility in the oral cavity and containing no polishing agent blended therein. CONSTITUTION: This foamy composition for the oral cavity contains >=0.2wt.% anionic surfactant (e.g. sodium laurylsulfate), 0.1-5wt.% nonionic surfactant (e.g. an alkyl fatty acid diethanolamide) or amphoteric surfactant (e.g. an alkylbetaine) and a viscous agent (e.g. a polyhydric alcohol) and/or a binder (e.g. hydroxyethyl cellulose) and further, as necessary, a perfume, a sweetener, a coloring matter, a preservative, a pharmacodynamically effective agent, ethanol, etc., blended therewith. At this time, the viscosity at 25 deg.C is kept at <=7P, preferably 0.05-1P and the composition for the oral cavity is filled in a nonaerosol type nongas atmospheric-pressure container for applying a pressure to the contents, mixing the contents with air and jetting the contents into a foamy shape by jetting thereof to afford the objective material.
PROBLEM TO BE SOLVED: To obtain an antitumor therapeutic agent manifesting antitumor activities by directly controlling cytotoxicity and vascularization around the tumor by including tetraarsenic hexoxide As4 O6 as an active ingredient. SOLUTION: This antitumor therapeutic agent contains (A) tetraarsenic hexoxide As4 O6 as an active ingredient. The antitumor therapeutic composition contains the component A and (B) a vehicle. The component A is preferably the one of a natural chemical material separated and purified from a natural arsenalite while removing toxicity by multistep heating. The component B is preferably a Chinese medicine, e.g. the one obtained by pulverizing a resin of Calophyllum inophyllum, Manis pentadactyla, Atractylodis rhizoma, gallstone of Bos taurus, 'SINNKYOKU' phonetic, Diospyros kaki, a resin of Dryobalanops camphora, olibanum, myrrh, bark of Morus bombycis, root of Pueraria lobata, Portulaca oleracea, fruit of Schizandra chinensis, gypsum, borax, white marble or the like to form a powder, or the like.
PURPOSE:To obtain the subject dispersion suitable for producing cosmetics or coatings having excellent ultraviolet light-screening performance. CONSTITUTION:This dispersion is an aqueous or oily dispersion comprising an aqueous or oily dispersion medium, iron-contg. ultrafine particulate titanium dioxide and a dispersant. In this case, the iron-contg. ultrafine particulate titanium dioxide has 0.01-0.1mum average single particle diameter and its crystal contains therein 1-30wt.% of iron components in terms of Fe, based on the TiO2. The dispersion can easily form a high-dispersion degree formulaiton system in cosmetics or coatings by using the iron-contg. ultrafine particulate titanium dioxide, being esp. suitable esp. in such a case that application of moderate dispersion energy is desired as in the case of cosmetic system. Besides, the resultant ultraviolet light-screening performance becomes more preferable when such iron-contg. ultrafine particulate titanium dioxide powder is formulated in cosmetics or coatings; in particular, in cosmetic system, this dispersion is highly suitable for suppressing bluish feeling and improving feeling in use and stability.
A method of providing and/or injecting octreotide acetate to a subject in need thereof includes storing the octreotide acetate in a cartridge of a multi-use multi-dose injector provided with a variable dose setter and actuator. The injector includes a needle configured for subcutaneous administration of the octreotide acetate, the octreotide acetate having a concentration of 2,500 μg/mL. The method further includes permitting setting of a dose of the octreotide acetate by rotation of the variable dose setter. The injector is configured to provide at least one audible feedback during the rotation. The method further includes operating the actuator to deliver the octreotide acetate from the cartridge through the needle to treat the subject. The injector is provided with multiple surface portions.
The invention discloses absorbent cotton for warming moxibustion and a preparation method thereof. The absorbent cotton selects medial absorbent cotton as a carrier, and is soaked into mixing solution of plant extract liquid for physical therapy operation and related drugs, and then tightly stored by a plastic bag after the absorbent cotton absorbs liquid medicine to saturate. The absorbent cotton is taken out in use, and put into a moxa burner, so that the liquid medicine is heated to evaporate; and the drug vapor fumes the skin of the physical therapy part, so as to carry out physical therapy on a sufferer. The absorbent cotton can be independently used or matched with the traditional physiotherapy device, so as to enhance the physical therapy effect; the plant extract liquid comprises the materials of folium artemisiae argyi or folium artemisiae argyi stem, camphor tree branches and leaves, fresh ginger, plant essential oil and mint oil. The absorbent cotton is tightly packaged after preparing materials, preparing the extract liquid and soaking. The absorbent cotton contains the plant extract liquid which has the effects of expelling wind-damp, clearing and activating the channels and collaterals, and activating blood and dissolving stasis, does not contain other chemical ingredients, is good in physical therapy effect, and does not damage a human body and the environment.
A one time lump sum of 200,000 UGX (\~$54) be provided to all study participants in a random sub-set of intervention (IPT-G) clusters near or at the conclusion of the 14-week therapy. This treatment variation will allow for determination of whether complimentary income support enhances the effects of IPT-G on psychological wellbeing and other outcomes of interest.
A method for treating pulmonary hypertension and other diseases involving a defect in collagen metabolism, by administration of an effective amount of a liposome encapsulated copolymer conjugate antifibrotic composition, is disclosed. The antifibrotic agent is preferably proline analogs, such as cis-4-hydroxy-L-proline (CHOP), 3,4-dehydro-DL-proline (DHP), (R)-(−)-2-thiazolidine-4-carboxylic acid (THP), and (S)-(−)-2-azetidinecarboxylic acid (ACA). Consistent, high loadings (>90%) of the antifibrotic agent are achieved by first forming a dipeptide with L-lysine, after which the dipeptide is copolymerized with the polymer component to form the copolymer conjugate. The polymer is preferably poly(ethylene glycol) having a weight average molecular weight of from about 500 to about 15,000. Efficient delivery and consistent release of the antifibrotic agent inhibits collagen accumulation and treats the diseases involved. Accordingly, there is a substantial reduction in the quantity of antifibrotic agent necessary, and thus a corresponding reduction in the potential for toxicity that would otherwise result from its prolonged administration.